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Abstract
Background: How to assess the impact of research is of growing interest to funders, policy makers and
researchers mainly to understand the value of investments and to increase accountability. Broadly speaking the
term “research impact” refers to the contribution of research activities to achieve desired societal outcomes. The
aim of this overview is to identify the most common approaches to research impact assessment, categories of
impact and their respective indicators.
Methods: We systematically searched the relevant literature (PubMed, The Cochrane Library (1990-2009)) and
funding agency websites. We included systematic reviews, theoretical and methodological papers, and empirical
case-studies on how to evaluate research impact. We qualitatively summarised the included reports, as well the
conceptual frameworks.
Results: We identified twenty-two reports belonging to four systematic reviews and 14 primary studies. These
publications reported several theoretical frameworks and methodological approaches (bibliometrics, econometrics,
ad hoc case studies). The “payback model” emerged as the most frequently used. Five broad categories of impact
were identified: a) advancing knowledge, b) capacity building, c) informing decision-making, d) health benefits, e)
broad socio-economic benefits. For each proposed category of impact we summarized a set of indicators whose
pros and cons are presented and briefly discussed.
Conclusions: This overview is a comprehensive, yet descriptive, contribution to summarize the conceptual
framework and taxonomy of an heterogeneous and evolving area of research. A shared and comprehensive
conceptual framework does not seem to be available yet and its single components (epidemiologic, economic,
and social) are often valued differently in different models.
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Background
It is widely accepted that research is a crucial
investment to foster innovation, knowledge advance-
ment, and social and economic development. For
example a knowledge gain is assumed to result from
biomedical and basic research; if such an output is then
properly translated in a short but reasonable time lag, it
will lead to a better health status for populations and
patients. Much of the information produced is not easily
transferable to patient care and this has led to the con-
cept of the so called “translational blocks” [1]. Evidence
produced by applied types of health research, such as
the “comparative effectiveness” and “health services
research” elicits its potential impact in a more straight-
forward way. Health care systems, which are nowadays
increasingly keen to directly support research, are inter-
ested in overcoming the translational blocks and to
facilitate a quicker return of their investment in terms
of information that would help selecting the more effec-
tive and cost effective interventions so that quality and
appropriateness can be maximised [2-4].
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By definition, research activities are risky and their
returns highly unpredictable. So, any attempt to increase
the research system’s effectiveness, and to assure and
monitor quality, is welcome by the whole scientific com-
munity and funders [5]. Competition on limited
resources and different funding modalities also raise
additional concerns. From the limited available evidence
on the proportion of investments by research stream,
funding is skewed toward biomedical and basic research
which, by definition, require more time to have an
impact [6]. This has raised a debate between those who
ask for a priority-setting based on the ability to produce
relevant, usable, and transferable outputs and those sup-
porting the view that research should be driven only by
the researchers’ interest. If left only into the close
boundaries of the “research communities”, there is a
concrete risk that the priority setting becomes self-refer-
ent and the “bidirectional dialogue” between those that
generate relevant questions from observation in clinical
practice and those that are responsible to generate the
new knowledge remains very limited [7]. Monitoring
and measuring research impact is a complex objective
requiring the involvement of many actors within the
research pipeline. In the past two decades, many theore-
tical frameworks and methodological approaches to
measure research impact and returns have been devel-
oped. The payback [8], the cost-benefit [9,10], and the
decision making impact models [11] are examples of
evaluation approaches reported in scientific and health
policy literature. A partial list with a qualitative descrip-
tion of the most common frameworks is reported in
Table 1. All these models share a multidimensional
approach achieved by categorizing impact and benefit in
many dimensions and trying to integrate them [12]. A
set of indicators and metrics are then generally asso-
ciated to each category of impact. For example, biblio-
metric indicators (e.g. impact factor) are highly reported
as a measure of the diffusion and awareness of research
results. These indicators, though welcome to some
extent because of their directness, are at best only surro-
gate measures of impact. Moving toward more robust
metrics, such as those measuring the health status or
the economic benefit of a population, is a complex task
but in some way essential [13].
The objective of this overview is to describe the con-
ceptual and methodological approaches to evaluate the
impact of biomedical and health research. Specifically,
we aimed at collecting and qualitatively summarizing
what is available in the biomedical literature in terms of
theoretical framework and methodologies, with a speci-
fic focus on the most valid and reliable indicators of
impact. Our objective was also to see whether this quali-
tative analysis would have allowed the identification of a
preferred model to measure research impact and to
identify the desirable elements (i.e. dimensions to be
considered, robust and reliable indicators) that a refer-
ence model should have.
Other key elements in the “research governance
debate” such as the analysis of different modes and
approaches to research funding, prioritization of topics,
or the analysis of barriers and facilitators to the transla-
tion of research results were beyond the scope of this
overview.
Methods
In the context of this overview, the term “research
impact” refers to any type of output of research activ-
ities which can be considered a “positive return” for the
scientific community, health systems, patients, and the
society in general. We refer to any type of health-related
research, basic and biomedical, such as new drug or
technology development - and applied research such as
clinical trials, health service research, and health tech-
nology assessment (HTA).
The complexity and heterogeneity of the topic made
the conceptualization of this overview much less
straightforward than typical review on medical interven-
tions. We therefore followed the methodology recom-
mended by the Cochrane Collaboration for preparing
“overviews of review” rather than following the steps
involved in critically appraising the primary studies for a
systematic review (SR) [14]. We first searched for SRs
summarizing theoretical model or methodological
approaches as well as empirical assessment of health
research funding programs. To increase the comprehen-
siveness of our search we also sought primary studies
(case studies) not included in the selected SRs or pub-
lished in languages other than English. We included stu-
dies describing conceptual or methodological
approaches to evaluate the impact of health research
programs and the empirical evaluation of specific pro-
grams, funders, research teams, clinical area, etc. In
both cases, to be eligible for this review the study should
have mentioned specific impact categories and the indi-
cators and metrics used to measure this impact.
Given the broad perspective of the review, the metho-
dology to identify relevant studies comprised an iterative
process. We first performed a systematic search on bib-
liographic databases (Medline and The Cochrane
Library) using a modified version of the search strategy
proposed by Martin Buxton and collaborators [12]. The
search was limited to the SRs published between 1990
and 2009. We also tried to include relevant studies and
reports not included in the eligible SRs (i.e. publications
in French, Italian, and Spanish) published between 2007
and 2009. Besides bibliographic databases, we screened
the research funding and Charity’s Foundations websites
cited in the eligible studies, looking for the grey
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Table 1 A qualitative description of the most widespread frameworks for the evaluation of research impact
Model Description Dimensions of impact
evaluation
Main proposed indicators Examples and Main
bibliographic
references
1. Payback Organizes together in a sequential and
systematic way the different aspects on
the impact of research projects from
dissemination to potential benefits for
health care
i) knowledge production;
ii) research targeting and
capacity building;
iii) informing policies and
product development;
iv) health benefit;
v) broader economic benefits.
i) journal articles, conference
presentations, books, research
reports, other disseminative
material;
ii) new research lines or know
how, career promotions, PhD,
masters;
iii) guidelines and documents
addressing policies citations,
membership of decision panels;
iv) health outcomes, QALY,
savings for health care systems
v) benefits in occupation and
economic development,
productivity
Research programs
financed by the NHS
UK [12,38,40,44]
2. Research
Impact
Evaluates the influence of research
results and of the potential concurrent/
competing factors (cultural context,
policy content, decision process) in
policy making
i) research related impact
ii) policy impact
iii) service impact
iv) societal impact
i) knowledge and methodology
advancements, networking,
leadership
ii) establishment of
collaborations and networks
iii) evidence-based practice; cost-
containment, quality of care;
iv) knowledge, attitudes and
behaviour, health literacy, social
capital, equity, macroeconomy
London School of
Hygiene and Tropical
Medicine researchers
evaluation [45]
3. Research
utilization
ladder
Evaluates the ways in which research
progresses towards its application by
practitioners and policy makers
i) transmission (of research
results to practitioners and policy
makers)
ii) cognition (reading and
understanding)
iii) reference (quoting of research
results in reports, studies,
actions)
iv) effort (to adopt research
results)
v) influence (on choices and
decisions)
vi) application
- [46]
4. Lavis
decision-
making
impact
model
Evaluates the impact on decision
making of any individual or organisation,
considering the target audience of
research and the resources available for
the assessment
i) policy makers are the ones
seeking research (user-pull)
ii) researchers actively
disseminating results (producer-
pull)
iii) researchers and policy-makers
are both involved actively
(exchange measures)
Process measures (if limited
resources are available)
Intermediate outcome measures
(by performing surveys)
Outcome measures (by
performing cases studies)
Canada
[11]
5. Weiss
Logic Model
Analyzes the ratio between input
(resources), process (activity) and results
of research (products)
i) initial benefits
ii) intermediate benefits
iii) long-term benefits
Output: publications
i) awareness of medical research
results in policy making
ii) any changes in practice
iii) any changes in well-being
and health
[47]
6. HTA
Organisation
assessment
framework
Effectiveness is measured by the ability
to impact on decision making
i) productivity
ii) capacity to attract and
maintain resources and to
mobilize external support
iii) culture and values
maintenance (independence in
action, transparency of the
process, accountability to
stakeholders)
i) volume and productivity of
outputs, quality,
comprehensiveness, and
accessibility
ii) measure of visibility and
credibility
Quebec Council on
Health Care
Technology, Canada
[48]
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literature (i.e. additional reports not indexed in biblio-
graphic databases). In fact, a large part of the literature
in this field would be made up of heterogeneous
publications and critical appraisal reports published by
the main funding agencies. Details on the search strate-
gies used and the searched websites are reported in
Additional file 1.
Finally, we screened the citations reported in the
included publications and assessed the literature in the
field already retrieved by authors. We did not contact
study or report authors.
Two reviewers independently selected relevant
publications by screening titles and abstracts. After the
retrieval of the selected full text publications and, if
needed, of associated publications, we extracted the fol-
lowing details: objective, country and setting, evaluation
time lag, conceptual model methodology, main results
and conclusions.
From the analysis of the literature and with reference
to the more widely accepted theoretical models we
attempted a description of the categories of impact
more frequently measured, focusing on the indicators
and metrics for each category.
Given the heterogeneity of study designs, the different
objectives and the lack of a standard methodology
between studies, we did not perform a quality assess-
ment of the methods used in different studies.
Results
From the bibliographic databases and web searches we
identified 1064 records. Among these 38 potentially
relevant publications were retrieved as full text
(Figure 1). Sixteen publications were excluded, i.e.
because descriptive, [15] or dealing with prioritization of
research topics rather than impact [16,17]. We included
22 publications, referring to 18 studies: four SRs
[12,18-21] and 14 primary studies [8,9,22-36]. For each
study, we synthesized the overall objective, scientific
area evaluated, country and setting, and the time lag of
the evaluation.
Hereafter we briefly presents the four SRs. For details
please refer to Additional file 2. The included SRs pre-
sented and discussed comparative analyses of theoretical
models and empirical evaluations performed in several
countries from 1990. They all used a public funder’s
viewpoint (e.g. central or regional governments, WHO).
Besides the evaluation of specific research programs,
each SR also reported a description of theoretical mod-
els used as a framework for the assessment and a more
or less explicit description of categories of impact and
indicators used in the evaluation. Both the reviews by
Hanney et al and the one from the Canadian Academy
of Health Science answered to the broad question “how
to measure research impact”. The first aimed at asses-
sing how the impact of the UK National Health Service
Table 1 A qualitative description of the most widespread frameworks for the evaluation of research impact (Continued)
7. Societal
Impact
framework
Research is considered as the valuation
of the communication of research
groups with relevant surroundings
(industry, general public, scientific
community, public and policy
institutions)
i) knowledge products
ii) knowledge exchange and
esteem
iii) knowledge use
iv) attractiveness
i) publications, patents, products
ii) presentations, consultancies,
and public lectures
iii) citations, product use
iv) further funding
Royal Netherlands
Academy of Arts and
Sciences 2002 [49,50]
8. Balanced
scorecard
Measures performance and drives
organizational strategy by incorporating
organisational aspects together with
financial performance
i) financial;
ii) customers;
iii) business process;
iv) learning and growth.
- [51]
Ontario University
Health Network [52]
9. Research
Assessment
Exercise
(RAE)
To produce quality profiles for each
submission of research activity made by
UK academic institutions
Three quality profiles are defined
(panel decides the weight given
to each profile):
i) research output (minimum
50%);
ii) research context (minimum
5%);
iii) other indicators (minimum
5%).
i) RAE1: staff information
(volume and type of contracts,
external collaborators), analysis
of funding for research fellows;
ii) RAE2: research output
(publications, patents, reports,
database, software, etc);
iii) RAE3: research scholarships
iv) RAE4: attractiveness for
external funding
v) RAE5a: further information on
groups of research (networking,
development of a research
culture, etc)
RAE 2008 [53]
10. Cost-
benefit
Analysis
Research impact evaluated in monetary
terms
i) savings for health care systems
(direct costs)
ii) savings for the community on
the whole (indirect costs)
i) QALY
ii) profits
NIH, USA
[54]
National Institute of
Health 1993 [55]
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Health Technology Assessment program should be
measured and collected the available models, their
strengths and weaknesses [12]. The latter was interested
in defining the impact of the Canadian health research
and to answer to the broad questions “is there a best
method to evaluate the impacts of health research in
Canada?” and “are there best metrics that could be used
to assess those impacts?” [20]. These SRs included
studies aimed at describing conceptual or methodologi-
cal approaches to evaluate the impact of health research
programs as well as empirical applications of different
assessment strategies (desk analysis, interview,
peer-review evaluation, case-studies, etc.) and tools for
measuring impact (indicators and metrics). The review
published by Buxton et al in 2004 focused on the esti-
mation of the economic value of research to society.
The review reported an analysis of benefits in terms of
direct cost savings to the healthcare system, commercial
development, healthy workforce, and intrinsic value to
society due to the health gain [18]. Lastly, Coryn et al.
have reported a comparative analysis of 16 national
models and mechanisms used to evaluate research and
allocate research funding [21].
Hereafter we briefly presents the results of the included
primary studies. For details please refer to Additional file
3. The studies covered a broad range of evaluation exer-
cises sponsored by public and private research funding
agencies. All studies have been conducted in UK, Austra-
lia, Canada, and USA, with few exceptions [26,32]. These
studies were highly heterogeneous in terms of the applied
theoretical frameworks and methodology. The unit under
evaluation included researchers (from one single
researcher to teams and whole institutions) but also med-
ical discipline (e.g. cardiovascular disease research) or
type of grants (e.g. from public institutions, charities,
foundations, etc.).
The large majority applied a bottom-up evaluation
approach, where information goes from any “producers”
of research to any target of research outputs [37]. Two
studies applied a more strictly econometric approach
used to estimate return on investments in a top down
manner [9,36]. The method often used were the desk
analysis, peer reviewer evaluation, interviews and ques-
tionnaires to principal investigators or to stakeholders
with a variety of roles in the research production and
utilization.
Across the majority of the SRs and primary studies,
research impact was assessed alongside several
dimensions, which can be grouped into five categories:
“advancing knowledge”, “capacity building”, “informing
decision-making”, “health benefits”, and “broad
socio-economic benefits”. Each category, further split
into subcategories, had a set of indicators and metrics
capable of providing the size of the impact (see Table 2).
The more frequently quoted dimensions of impact were
advancing knowledge (using bibliometric and citational
approaches), capacity building (mainly using a desk ana-
lysis approach), and informing decision-making (through
the evaluation of how and to what extent research
findings are included into the decisional processes,
1034 records identified through 
database searching 
(MedLine and The Cochrane Library)
38 full text publications assessed for 
eligibility 16 publications excluded
Main reason for exclusion:
• descriptive studies
•prioritarisation of research
•Non-health topics
22 publications reporting data on 18 
studies included in qualitative 
synthesis
4 systematic reviews 14 primary studies
30 records identified through other sources
• research funding and evaluation agency websites
•known literature 
Figure 1 Flow of studies through the different phases of the overview.
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Table 2 Description of possible impact categories and relative indicators (adapted from Canadian Academy of Health
Science [20])
Impact
category
Proposed Indicators Data
collection
methodology
Level of
application
Theoretical Models
quoting this
category
Advantages Disadvantages
Advancing
knowledge
• Activity (number of peer-
reviewed publications
absolute or relative - e.g. to
the department
publications);
• Quality (impact factor,
relative citation impact, high
impact publications,
download numbers);
• Outreach (co-author
analysis, field analysis of
citations);
• Context and structure
(relative activity index);
• Other possible indicators
(expanded relative citation
impact, relative download
rate).
Bibliometric
and citational
analysis; desk
analysis.
Basic, clinical,
applied and social
research.
Assessment of
individual
researchers, teams,
institution, projects,
funding agencies.
Payback, research
impact, research
utilization ladder,
Lavis decision-making
impact model,
societal impact, RAE
-wide range of
applications
-close to
research itself
-objective
-attributed
relatively
straightforwardly
-accessibility and
feasibility
-limited cost
-surrogate indicators;
-not always relevant;
-not comparable
across different
disciplines;
-robust only if based
on a sufficient set of
publications (not fully
appropriate to
individual researcher
evaluation).
Capacity
building
• Staff (number of PhD,
Master, researchers, member
of staff);
• Funding (external sources
of funding);
• Infrastructure (grant for
infrastructure and
coordination activities);
• Other possible indicators
(receptor and absorptive
capacity)
Desk analysis,
database and
interviews
Basic, clinical,
applied and social
research
Assessment of
teams, institution,
projects, funding
agencies. Not
recommended at
individual level.
Payback, research
impact, research
utilization ladder,
Lavis decision-making
model societal
impact, RAE
-wide range of
applications
-quite close to
research itself
-attributed
relatively
straightforwardly
(partially)
-accessibility and
feasibility
-limited cost
–surrogate indicators;
-quite subjective;
-attribution issues;
-self referenced;
-non mutually
exclusive (double
counting)
Informing
policies and
product
development
• Health care (guidelines and
policy documents citations -
e.g. regional plans,
educational material, panel
representatives)
• Research (references used
as background for successful
funding proposals,
consulting and support
activity, curricula citations)
• Industrial (patents and
industrial collaboration,
clustering)
• Citizens (informative
packages, dissemination
activities)
• Media (journals, radio, tv,
web)
Desk analysis,
database and
interviews
Clinical, applied,
social research
Assessment of
individual
researchers, teams,
institution, projects,
funding agencies.
Payback, research
impact, research
utilization ladder,
Lavis decision-making
model,
societal impact
-Optimal for
projects funded
ad hoc to inform
decision making
-robustness
-relevance
-feasibility
-limited cost
-limited spectrum of
application
-time-lag between
input (research) and
output (result)
–quite subjective
-self referenced
Health and
health sector
benefits
• Health (Epidemiologic data,
incidence, prevalence,
mortality QALYs1, PROMs2)
• Health determinants (risk
factors, educational and
social level of cohesion,
pollution)
• System (patient satisfaction,
waiting lists, compliance and
adherence to clinical
guidelines, hospitalization,
length of inpatient stay,
adverse effects/
complications)
Desk analysis,
database and
interviews
Case studies,
audit
Clinical and
applied research
Evaluation of
teams, institutions,
projects, funding
agencies
Payback, research
impact, research
utilization ladder
-robustness
-relevance
-many confounders
-feasibility and cost of
data collection;
-time-lag between
input (research) and
output (result)
-possible
underestimation of
real impact
-attribution issue
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i.e. guidelines). The potential benefits of a research
activity on population’s health or its socio-economic sta-
tus were more rarely addressed by the literature as they
are, obviously, less directly linked and more complex to
assess. In other words, these categories, with their respec-
tive indicators, span into a gradient going from surrogate
but easy to be measured outcomes, (i.e. bibliometric and
citational data) to demanding but relevant outcomes (i.e.
morbidity, quality of life). Bibliometric indicators (num-
ber of publications, impact factor, citation indexes, etc.)
were a case in point here. They were widely considered,
reported, and to some extent, accepted due to the fact
that they are easy to measure and outputs that can be
straightforwardly attributed to a specific research activity.
Only the studies adopting an econometric viewpoint [18]
or evaluating a specific research area, such as primary
care [27,28] or health system effectiveness [29] did not
quote (or quoted with less emphasis) bibliometric
indicators.
Discussion
Main findings
This overview of reviews shows that the assessment of
the impact of, or benefits from, health research is an
issue of growing interest, mainly in those countries (UK,
Canada, Australia, USA) that invest more in research.
Research in this area focuses on three broad areas:
i) theoretical frameworks and models aiming at asses-
sing research impact with respect to multidimensional
and integrated categories; ii) methodological approaches
to the evaluation exercise; and iii) development of valid
and reliable indicators and metrics.
A common and key feature of most of the used mod-
els is the multidimensional conceptualization and cate-
gorization of research impact. Different impact aspects
are connected and integrated using a variety of theoreti-
cal approaches (i.e. Logic model for the Payback frame-
work). Assessment of research impact that consider
more than one category are indeed valued for their abil-
ity to capture multifaceted processes.
Several empirical approaches have been used to
practically assess research impact: desk analysis, includ-
ing bibliometrics, peer reviews, interviews, ad hoc case
studies. The latter seems a reliable methodology: case
study implies an explicit and a priori choice to start and
conduct an evaluation exercise with specific aims and
features. However, they can be at risk of “conceptualiza-
tion bias” and “reporting bias” especially when they are
designed or carried out retrospectively. Finally, feasibility
and costs of case studies are also a major barrier to their
conduct and subsequent use. In general, the methodol-
ogy should be as flexible and adaptable as possible to
many assessment questions, viewpoints, settings, and
type of research and should guarantee the quality of
collected data.
The lack of standard terminology, the multifaceted
nature of the evaluation, and the heterogeneity of the
empirical experiences make it hard to identify a pre-
ferred model. The most cited impact dimensions are
related to knowledge, public health and socio-eco-
nomic advancements. The Payback model, [38-41] and
its adaptation into the Canadian framework [20]
emerged as the most frequently quoted. Both are based
on explicit assumptions (positive and negative), have
been applied to empirical evaluation, and produce
transparent categories of impact, indicators, and limita-
tions of the models. They can be considered compre-
hensive as assure a global approach to the evaluation
of biomedical and health research impact. The identifi-
cation of appropriate indicators is a critical step in any
impact assessment exercise, and assessing research
impact makes no exception to this. Indicators can be
defined as factors or variables that provide simple and
reliable means to measure impact, changes to an inter-
vention, or performance [42]. Ideally, a set of a few
robust, valid, shared, transferable, comparable, and fea-
sible indicators able to synthesize research impact
should be developed for any assessment. As a matter
of fact, the usefulness of indicators highly depends on
the evaluation purposes and the level of aggregation of
Table 2 Description of possible impact categories and relative indicators (adapted from Canadian Academy of Health
Science [20]) (Continued)
Economic
and social
benefits
• Economic rent (salaries,
employments)
• Licensing returns
• Product sales revenues
• Spin-off companies
• Health benefit (QALY and
PROM per health care dollar)
• Well-being (happiness, level
of social isolation)
• Social benefits (socio-
economic social)
Desk analysis,
database and
interviews
Case studies,
audit
Econometrics
Clinical and
applied research
Evaluation of
teams, institutions,
projects, funding
agencies
Payback, societal
impact, cost-benefit.
-robustness
-relevance
-many confounders
-feasibility and cost of
data collection;
-time-lag between
input (research) and
output (result)
-possible
underestimation of
real impact
-attribution issue
-use of models and
assumptions
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the unit of analysis: for instance, citation indicators
partially capture the impact on knowledge advance-
ments as they only consider published literature, they
are artificially skewed by journal’s impact factor and
can be misleading when applied to individuals. More-
over, an indicator itself informs only on a single aspect
of research impact, thus sets of indicators are always
advisable.
This overview highlights the methodological limita-
tions of the studies carried out in this field, which are
briefly summarized below.
First, the vast majority of the studies were retrospec-
tive, based on interviews to principal investigators or
funders, and mainly focused to record the projects ’
achievements rather that their pitfalls and limitations.
This could lead to several biases, such as selective
recall or reporting of (positive) results. The second
major limitation is linked to the “attribution”, the pos-
sibility to postulate a causal link between observed (or
expected to be observed) changes and a specific
research activity [19]. Another limitation is linked to
the possibility of understanding what would have hap-
pened without “that” research activity (counterfactual).
As very rarely a “control” situation is available, the
identification of baseline measures and context factors
is important in understanding what any counterfactual
might have looked like. Finally, it is not commonly
appreciated that substantial time lags exist between
research funding and measurement of outputs. An
impact assessment should be planned choosing an
appropriate time window, which highly depends on the
considered type of research and dimension of the
impact.
Limitations of this overview
The main limitations of this overview concern the
study retrieval process and the definition of the elig-
ibility criteria. We experienced several difficulties in
planning the search strategy, all caused by the hetero-
geneity of definition and the lack of a standard termi-
nology to describe “research impact”. Bearing this in
mind, we adopted an approach capable of maximizing
sensitivity rather than specificity, that is the application
of broad inclusion criteria and the use of several
sources of information, not only bibliographic data-
bases. As expected, only 30% of the included publica-
tions were found through the traditional biomedical
databases (i.e. Medline). Beyond a high variability in
the way of indexing these articles, this could be due to
a limited interest in the publication of these evalua-
tions, which were considered, at least in the last dec-
ade, an administrative duty rather than a scientific
activity. Thus many relevant studies were retrieved in
the “grey literature” (i.e. funding agency’s reports) and
not in scientific journals. Even if we were not able to
apply a systematic approach to website consultation,
we believe this effort had increased the comprehensive-
ness of our search.
Another methodological limitation of this overview is
that we did not estimate the level of publication bias
and selective publication in this field. Finally, as our
analysis include study up to 2009, we did not capture
new important emerging approaches to impact assess-
ment, such as the Research Excellence Framework (for-
merly RAE) [43].
Conclusions
The main message of this overview is that the evaluation
of the research impact is as yet a heterogeneous, and
evolving discipline. Multidimensional conceptual frame-
works appear to be adequate as they take into account
several aspects of impact and use advanced and analyti-
cal approaches (i.e. epidemiologic, economic, and social)
to their evaluation. It remains to be clarified how differ-
ent impact dimensions should be valued and balanced
by assessors to fit them to their specific purposes and
contexts. Added values to the multidimensional
approach are to pursue an explicit planning of the
assessment exercise and to carried out the alongside the
development of research programs, through monitoring
and prospective data collection.
This overview should be seen as a preliminary step
toward a shared conceptual framework and taxonomy to
assess research impact rather than an indication of an
ultimate model, that probably appears unrealistic.
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